GlassScriptPhysician profile
David Engar Warner
NPI 1407266208
$2,714.14
in general payments reported to CMS, 2019-2025
16 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $44.21 · 2021: $13.52 · 2022: $194 · 2023: $106 · 2024: $2,179 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,070 · Food and Beverage: $367 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,070.00 |
| Food and Beverage | $366.74 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $2,070.00 | 2024 | Ogsiveo |
| Daiichi Sankyo INC. | $176.37 | 2020-2025 | Enhertu |
| Kite Pharma, INC. | $106.28 | 2022 | |
| Celgene Corporation | $53.29 | 2023-2025 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $46.23 | 2023-2025 | Eliquis |
| Novartis Pharmaceuticals Corporation | $43.46 | 2022 | |
| Lilly USA, LLC | $37.56 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Beone Medicines USA, INC. | $34.89 | 2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $25.95 | 2024 | Enhertu |
| Beigene USA, INC. | $23.55 | 2024 | Brukinsa |
| Genmab U.S., INC. | $21.62 | 2023 | Tivdak |
| Pfizer INC. | $18.70 | 2023 | |
| Gilead Sciences, INC. | $15.81 | 2024 | |
| Merck Sharp & Dohme LLC | $14.06 | 2025 | Lynparza, Keytruda |
| Epizyme, INC. | $13.52 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $12.85 | 2023 | Tukysa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.